Eli Lilly and Novo Nordisk, two of the largest pharmaceutical companies globally, have experienced significant growth since entering the weight loss market, with the former's value increasing by 108% since it entered this lucrative niche in 2023.
This makes Lilly the second most valuable pharmaceutical brands, totalling $8bn.
Novo Nordisk, another big pharma company hedging its bets on weight loss, has seen a brand value increase of 130% since 2022 — which Brand Finance believes is driven by its weight loss and diabetes offerings.
Both pharmaceutical giants have supported their growth with the worldwide distribution of their efficacious weight loss drugs, as well as targeted acquisitions that boost their standings in this sector.
Currently, Johnson & Johnson is the world's most valuable pharmaceutical brand, standing at a huge $15.5bn, with a brand strength index of 83.5 out of 100.
The company's consumer health division spinoff, Kenvue, further fuels the pharmaceutical giant's growth.
"The top 25 most valuable brands in the pharmaceutical and medical devices sectors have seen modest aggregate growth of 1% and 5%, respectively, over the past year," noted Hugo Hensley, Valuation Director, Brand Finance.
"While overall expansion remains steady, innovation continues to be a key driver of growth."
"Breakthrough treatments have propelled brands like Novo Nordisk and Lilly to new heights - Lilly is the fastest-growing among the top 25 pharma brands, with a 36% year-on-year increase," he concluded.